This article was originally published in Start Up
Service Carveouts; Disease Management; Urology. UroTherapies Inc., a new physician practice management company dedicated to urology, hopes to combine the best urology groups and the latest technology to sell to managed care organizations.UroTherapies offers to take on risk by caring for high cost patients on a capitated basis.
You may also be interested in...
Despite its failures, disease management remains a compelling need, perhaps because it's so clear that payers and providers require something to organize the increasingly expensive fragmentation of the health care system.
New technologies enable the rapid processing of genetic information, but since gene data isn't associated with specific diseases and diseased tissues, in and of itself it isn't clinically useful. A new breed of start-ups aims to provide both the phenotypic and genotypic sides of the equation by creating databases of patients and patient samples. Still unclear is how much drug firms will pay for disease-associated gene data; genetics firms are taking various approaches to monetizing their databases, from focusing initially on high-value diagnostics to creating true target-discovery businesses, to selling their data along with associated software and services. There are also ethical issues to hammer out. The new companies must take care to protect patients' rights. They must consider the need for explicit consent to use the information collected from patients, especially when they are participating in research whose purpose is as yet undefined.
Despite a history of failed products, start-up companies are looking to reinvent how data from clinical trials is collected and managed. Firms are trying to replace the point solutions of the past with broad software offerings that can take clients from "site to submission."